Drugs / Sepetaprost
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05905653 | May → Jun 2023 | — | Santen Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01670266 | Aug 2012 → May 2013 | ocular hypertension, open-angle glaucoma | Ono Pharma USA Inc | Completed | No outcome recorded |
| Phase 1 | NCT01508988 | Jan → Apr 2012 | — | Ono Pharma USA Inc | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT04742283 | Dec 2020 → Dec 2021 | ocular hypertension, open-angle glaucoma | Santen Inc. | Completed | Met primary |
| Phase 2 | NCT03216902 | Jul 2017 → Feb 2018 | open-angle glaucoma | Santen Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02083289 | May → Dec 2014 | ocular hypertension, open-angle glaucoma | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05495061 | Aug 2022 → Apr 2023 | ocular hypertension, open-angle glaucoma | Santen Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05503901 | Aug 2022 → Jan 2024 | open-angle glaucoma | Santen Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-08-25 | Santen Gmbh | Regulatory Santen Obtains Manufacturing and Marketing Approval in Japan for SETANEO® 0.002% Ophthalmic Solution, a Bicyclic Prostaglandin Derivative that Acts on FP and EP3 Receptors, for Treatment of Glaucoma and Ocular Hypertension santen.com ↗
Santen Pharmaceutical Co., Ltd. (hereinafter Santen) announced today that it has obtained manufacturing and marketing approval in Japan for SETANEO® ophthalmic solution 0.002% (generic name: sepetaprost; development code: STN1012600; hereinafter the product) for the treatment of glaucoma and ocular hypertension. |
| 2024-09-26 | Santen Gmbh | Regulatory Santen applies for manufacturing and marketing approval in Japan for STN1012600 ophthalmic solution (sepetaprost ophthalmic solution), a treatment for glaucoma and ocular hypertension with a novel mechanism of action for lowering intraocular pressure santen.com ↗
Santen Pharmaceutical Co., Ltd. (hereinafter Santen) announced today that it has filed an application for manufacturing and marketing approval of STN1012600 (generic name: sepetaprost) in Japan. |
All press releases naming this drug 2 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sepetaprost | “Sepetaprost is a novel investigative prodrug, the active form of which is a dual agonist targeting both prostaglandin F receptors and prostaglandin E receptor 3.” PMID 40043909 ↗ Mar 2025 |
| Known as | DE-126 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03216902 ↗ |
| Known as | ONO-9054 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02083289 ↗ |
| Known as | Sepetoprost | “ONO-9054 (Sepetoprost), the prodrug of ONO-AG-367” PMID 26720443 ↗ Dec 2015 |
| Known as | STN1012600 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05503901 ↗ |
| Action | Activate | “novel EP3 and FP receptor agonist ONO-9054” PMID 26720443 ↗ Dec 2015 |
| Modality | Small molecule | — CHEMBL4297633 ↗ |
| Route | Other | “Experimental Eye drops 3.0 µg/mL QD both eyes on Day 1, 5-18” NCT01670266 ↗ |
| Target | PTGER3 | “Prostanoid EP3 receptor agonist” CHEMBL4297633 ↗ |
| Target | PTGFR | “Prostanoid FP receptor agonist” CHEMBL4297633 ↗ |